Humacyte, Inc. (HUMA) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/17/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
March 27, 2026 7:00 AM EDT- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year -Â
- Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia -
- Submitted of a Marketing Authorization Application with the Israel Ministry of Health -
- U.S. Department of Defense authorized funding for procurement of bioengineered blood vessels -
- Major milestone upcoming:... More



